Chlamydia pneumoniae and vascular disease

British Journal of Surgery

Volumn 85, Issue 9, 1998, Pages 1191-1197

  Gibbs, R G J ^a   Carey, N ^a   Davies, A H ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE;

ANIMAL MODEL; ARTERY DISEASE; ATHEROSCLEROSIS; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CELL CULTURE; CHLAMYDOPHILA PNEUMONIAE; CYTOKINE RELEASE; ELECTRON MICROSCOPY; HEART INFARCTION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; IN SITU HYBRIDIZATION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LITERATURE; LUNG INFECTION; MEDICAL INFORMATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROEPIDEMIOLOGY; VASCULAR TISSUE;

ANTI-BACTERIAL AGENTS; ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIALS; HUMANS; MACROLIDES;

EID: 0031684486     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00861.x     Document Type: Review

References (87)

1. Dawson CR, Jones BR, Tarizzo ML. Guide to trachoma control in programmes for the prevention of blindness. Geneva: World Health Organization, 1981.
2. Sexually Transmitted Diseases. World Health Organization Press Release WHO/64, 1995. Health Communications and Public Relations (IWF), WHO, Geneva.
3. Schachter J, Dawson CR. Psittacosis. Human Chlamydial Infections. Littleton, Massachusetts: PSG Publishing, 1978.
4. Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992; 15: 757-61.
5. Campbell LA, Kuo CC, Grayston JT. Structural and antigenic analysis of Chlamydia pneumoniae. Infect Immun 1990; 58: 93-7.
6. Ward ME. The immunobiology and immunopathology of chlamydial infections. APMIS 1995; 103: 769-96.
7. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydial psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161-8.
8. Leinonen M. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J 1993; 14(Suppl K): 57-61.
9. Grayston JT, Campbell LA, Kuo CC, Mordhurst CH, Saikku P, Thom DH et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-25.
10. Saikku P, Leinonen M, Mattila KJ, Ekman MR, Nieminen MS, Makela PH et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; ii: 983-6.
11. Hahn DL, Golubjatnikov R. Smoking is a potential confounder of the Chlamydia pneumoniae coronary artery disease association. Arteriosclerosis and Thrombosis 1992; 12: 945-7.
12. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman M-R, Manninen V et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116: 273-7.
13. Linnanmaki E, Leinonen M, Mattila K, Nieminen MS, Valtonen V, Saikku P. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993; 87: 1130-4.
14. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J et al. Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart disease. J Infect 1995; 30: 121-8.
15. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995; 311: 711-14.
16. Thom DH, Grayston JT, Siscovick DS, Wang S-P, Weiss NS, Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992; 268: 68-72.
17. Melnick S, Shahar E, Folsom AR, Grayston JT, Sorlie PD, Wang S-P et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993; 95: 499-504.
18. Wimmer ML, Sandmann Strupp R, Saikku P, Haberl RL. Association of chlamydial infection with cerebrovascular disease. Stroke 1996; 27: 2207-10.
19. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992; 82: 158-61.
20. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167: 841-9.
21. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arteriosclerosis and Thrombosis 1993; 13: 1501-4.
22. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A 1995; 92: 911-14.
23. Campbell LA, O'Brien ER, Cappuccio AL, Kuo CC, Wang SP, Stewart D et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995; 172: 585-8.
24. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92: 3397-400.
25. Ong G, Thomas BJ, Mansfield AO, Davidson BR, Taylor Robinson D. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications. J Clin Pathol 1996; 49: 102-6.
26. Weiss SM, Roblin PM, Gaydos CA, Cummings P, Patton DL, Schulhoff N et al. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis 1996; 173: 957-62.
27. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27: 1555-61.
28. Blasi F, Denti F, Erba M, Cosentini R, Raccanelli R, Rinaldi A et al. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. J Clin Microbiol 1996; 34: 2766-9.
29. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996; 125: 979-82.
30. Juvonen J, Juvonen T, Laurila A, Alakarppa H, Lounatmaa K, Surcel HM et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997; 25: 499-505.
31. Juvonen J, Laurila A, Juvonen T, Alakarppa H, Surcel HM, Lounatmaa K et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1997; 29: 1054-9.
32. Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ et al. Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis. Am J Pathol 1997; 150: 1785-90.
33. Chiu B, Viira E, Tucker W, Fong IW. Chlamydia pneumoniae, cytomegalovirus and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997; 96: 2144-8.
34. Kuo CC, Coulson AS, Campbell LA, Capuccio MS, Lawrence RD, Wang SP et al. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction. J Vasc Surg 1997; 26: 29-31.
35. Maass M, Krause E, Engel PM, Kruger S. Endovascular presence of Chlamydia pneumoniae in patients with haemodynamically effective carotid artery stenosis. Angiology 1997; 48: 699-706.
36. Maass M, Gieffers J. Cardiovascular disease risk from prior Chlamydia pneumoniae infection can be related to certain antigens recognized in the immunoblot profile. J Infect 1997; 35: 171-6.
37. Maass M, Krause E, Kruger S, Engel PM, Bartels C. Direct demonstration of C. Pneumoniae in atherosclerotic lesions and in circulating blood cells. Fourth International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. May 1997. Abstract 101. Yverdun Les Bains, Switzerland.
38. Naidu BR, Ngeow YF, Kannan P, Jeyamalar R, Khir A, Khoo KL et al. Evidence of Chlamydia pneumoniae infection obtained by the polymerase chain reaction (PCR) in patients with acute myocardial infarction and coronary heart disease. J Infect 1997; 35: 199-200 (Letter).
39. Moazed TC, Kuo C, Patton DL, Grayston JT, Campbell LA. Experimental rabbit models of Chlamydia pneumoniae infection. Am J Pathol 1996; 148: 667-76.
40. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997; 35: 48-52.
41. Moazed TC, Kuo C, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Inject Dis 1997; 175: 883-90.
42. Kaukoranta Tolvanen SS, Luitinen K, Saikku P, Leinonen M. Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 1994; 16: 313-19.
43. Godzik KL, O'Brien ER, Wang SK, Kuo CC. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J Clin Microbiol 1995; 33: 2411-14.
44. Valtonen VV. Infection as a risk factor for infarction and atherosclerosis. Ann Med 1991; 23: 539-43.
45. Patel P, Carrington D, Strachan DP, Leatham E, Goggin P, Northfield TC et al. Fibrinogen: a link between chronic infection and coronary heart disease. Lancet 1994; 343: 1634-5 (Letter).
46. Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ 1996; 312: 1061-5.
47. Fryer RH, Schwobe EP, Woods ML, Rodgers GMJ. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med 1997; 45: 168-74.
48. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997; 96: 4095-103.
49. Heinemann M, Susa M, Simnacher U, Marre R, Essig A. Growth of Chlamydia pneumoniae induces cytokine production and expression of CD14 in a human monocytic cell line. Infect Immun 1996; 64: 4872-5.
50. Kaukoranta Tolvanen SS, Teppo AM, Laitinen K, Saikku P, Linnavuori K, Leinonen M. Growth of Chlamydia pneumoniae in cultured human blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996; 21: 215-21.
51. Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol 1995; 25(Suppl 2): 13-19.
52. Pober JS. Cytokine-mediated activation of vascular endothelium: physiology and pathology. Am J Pathol 1988; 133: 426-33.
53. Tewari A, Buhles WC Jr, Starnes HF Jr. Preliminary report: effects of interleukin-1 in platelet counts. Lancet 1990; 336: 712-14.
54. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 1996; 121: 185-91.
55. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-23.
56. Terry CM, Callahan KS. Protein kinase C regulates cytokine induced tissue factor transcription and procoagulant activity in human endothelial cells. J Lab Clin Med 1996; 127: 81-93.
57. Lopes-Virella MF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993; 14(Suppl K): 118-24.
58. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-6.
59. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B for the ROXIS Study Group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet 1997; 350: 404-7.
60. Haverkate F, Thompson FG, Pyke SDM, Gallimor JR, Pepys MB. for the European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet 1997; 349: 462-6.
61. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; i: 415-19.
62. The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chronic Dis 1976; 29: 625-42.
63. Breddin K, Loew D, Lechner K, Oberla K, Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicilic acid, placebo and phenprocoumon. Haemostasis 1980; 9: 325-44.
64. Elwood PC, Sweetnam PM. Aspirin and second mortality after myocardial infarction. Lancet 1979; ii: 1313-5.
65. Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9.
66. The Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 1980; 62: 449-61.
67. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
68. Steer KA, Wallace TM, Bolton CH, Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart 1997; 77: 333-7.
69. Scandanavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandanavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
70. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol 1995; 26: 1133-9.
71. Crouse JR III, Byington RP, Bond MG, Espeland MA, Craven TE, Sprinkle JW et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 75: 455-9.
72. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528-40.
73. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994 ; 90: 1679-87.
74. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
75. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lowering cholesterol. Lancet 1996; 348: 1079-82.
76. Anestad G, Scheel O, Hungnes O. Chronic infections and coronary heart disease. Lancet 1997; 350: 1028 (Letter).
77. Franklin IJ, Powell JT. The action of tetracyclines on connective tissue: towards medical therapies for aortic aneurysms. Angiology and Vascular Surgery 1998; (in press).
78. Petrinec D, Liao S, Holmes DR, Reilly JM, Parks WC, Thompson RW. Doxycycline inhibition of aneurysmal degeneration in an elastase induced rat model of abdominal aortic aneurysm: preservation of aortic elastin associated with suppressed production of 92 kD gelatinase. J Vasc Surg 1996; 23: 336-46.
79. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P. Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 1996; 16: 1070-3.
80. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-8.
81. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Alpers CE et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148: 777-83.
82. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a denned population. Circulation 1985; 71: 510-15.
83. Gibbs RGJ, Todd JC, Irvine C, Lawrenson R, Newson R, Greenhalgh RM et al. Relationship between the regional and national incidence of transient ischaemic attack and stroke and performance of carotid endarterectomy. Eur J Vasc Endovasc Surg 1998; 16: 47-52.
84. Minick CR, Fabricant CG, Fabricant J, Litrenta MM. Atheroarteriosclerosis induced by infection with a herpes virus. Am J Pathol 1979; 96: 673-706.
85. Fabricant CG, Fabricant J, Litrenta MM, Minick CR. Virus-induced atherosclerosis. J Exp Med 1978; 148: 335-40.
86. Melnick JL, Adam E, DeBakey ME. Possible role of cytomegalovirus in atherogenesis. JAMA 1990; 263: 2204-7.
87. Hajjar DP, Pomerantz KB, Falcone DJ, Weksler BB, Grant AJ. Herpes simplex virus infection in human arterial cells: implications in atherosclerosis. J Clin Invest 1987; 50: 1317-21.